Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells

Post-Covid pulmonary fibrosis is evident following severe COVID-19. There is an urgent need to identify the cellular and pathophysiological characteristics of chronic lung squeals of Covid-19 for the development of future preventive and/or therapeutic interventions. Tissue-resident memory T (T(RM))...

Descripción completa

Detalles Bibliográficos
Autores principales: Zununi Vahed, Sepideh, Hosseiniyan Khatibi, Seyed Mahdi, Ahmadian, Elham, Ardalan, Mohammadreza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Masson SAS. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8723825/
https://www.ncbi.nlm.nih.gov/pubmed/34995938
http://dx.doi.org/10.1016/j.biopha.2022.112614
_version_ 1784625803383799808
author Zununi Vahed, Sepideh
Hosseiniyan Khatibi, Seyed Mahdi
Ahmadian, Elham
Ardalan, Mohammadreza
author_facet Zununi Vahed, Sepideh
Hosseiniyan Khatibi, Seyed Mahdi
Ahmadian, Elham
Ardalan, Mohammadreza
author_sort Zununi Vahed, Sepideh
collection PubMed
description Post-Covid pulmonary fibrosis is evident following severe COVID-19. There is an urgent need to identify the cellular and pathophysiological characteristics of chronic lung squeals of Covid-19 for the development of future preventive and/or therapeutic interventions. Tissue-resident memory T (T(RM)) cells can mediate local immune protection against infections and cancer. Less beneficially, lung T(RM) cells cause chronic airway inflammation and fibrosis by stimulating pathologic inflammation. The effects of Janus kinase (JAK), an inducer pathway of cytokine storm, inhibition on acute Covid-19 cases have been previously evaluated. Here, we propose that Tofacitinib by targeting the CD8(+) T(RM) cells could be a potential candidate for the treatment of chronic lung diseases induced by acute SARS-CoV-2 infection.
format Online
Article
Text
id pubmed-8723825
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-87238252022-01-04 Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells Zununi Vahed, Sepideh Hosseiniyan Khatibi, Seyed Mahdi Ahmadian, Elham Ardalan, Mohammadreza Biomed Pharmacother Article Post-Covid pulmonary fibrosis is evident following severe COVID-19. There is an urgent need to identify the cellular and pathophysiological characteristics of chronic lung squeals of Covid-19 for the development of future preventive and/or therapeutic interventions. Tissue-resident memory T (T(RM)) cells can mediate local immune protection against infections and cancer. Less beneficially, lung T(RM) cells cause chronic airway inflammation and fibrosis by stimulating pathologic inflammation. The effects of Janus kinase (JAK), an inducer pathway of cytokine storm, inhibition on acute Covid-19 cases have been previously evaluated. Here, we propose that Tofacitinib by targeting the CD8(+) T(RM) cells could be a potential candidate for the treatment of chronic lung diseases induced by acute SARS-CoV-2 infection. The Authors. Published by Elsevier Masson SAS. 2022-03 2022-01-04 /pmc/articles/PMC8723825/ /pubmed/34995938 http://dx.doi.org/10.1016/j.biopha.2022.112614 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Zununi Vahed, Sepideh
Hosseiniyan Khatibi, Seyed Mahdi
Ahmadian, Elham
Ardalan, Mohammadreza
Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells
title Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells
title_full Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells
title_fullStr Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells
title_full_unstemmed Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells
title_short Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells
title_sort targeting chronic covid-19 lung injury; tofacitinib can be used against tissue-resident memory t cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8723825/
https://www.ncbi.nlm.nih.gov/pubmed/34995938
http://dx.doi.org/10.1016/j.biopha.2022.112614
work_keys_str_mv AT zununivahedsepideh targetingchroniccovid19lunginjurytofacitinibcanbeusedagainsttissueresidentmemorytcells
AT hosseiniyankhatibiseyedmahdi targetingchroniccovid19lunginjurytofacitinibcanbeusedagainsttissueresidentmemorytcells
AT ahmadianelham targetingchroniccovid19lunginjurytofacitinibcanbeusedagainsttissueresidentmemorytcells
AT ardalanmohammadreza targetingchroniccovid19lunginjurytofacitinibcanbeusedagainsttissueresidentmemorytcells

Ejemplares similares